EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EX NRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MI
EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EX NRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EXNRNP 6675 MIDTERM EX AM (YEAR 2022 AM (YEAR 2022 AM (YEAR 2022 AM (YEAR 2022 AM (YEAR 2022 AM (YEAR 2022 AM (YEAR 2022 AM (YEAR 2022 – 100/ 100 POINTS) LATEST UPDAT POINTS) LATEST UPDATPOINTS) LATEST UPDATPOINTS) LATEST UPDAT POINTS) LATEST UPDATPOINTS) LATEST UPDATPOINTS) LATEST UPDATPOINTS) LATEST UPDAT POINTS) LATEST UPDATPOINTS) LATEST UPDATPOINTS) LATEST UPDATPOINTS) LATEST UPDATPOINTS) LATEST UPDATPOINTS) LATEST UPDATPOINTS) LATEST UPDATE 1. Which of the following are risk factors for neuroleptic malignant syndrome? Select all that apply Age Rapid dose escalation Parental route of administration Higher potency typical antipsychotics 2. Antipsychotic medications provide D2 blockade in the mesocortical pathway causing which of the following effects? Reduces negative symptoms Increases extra pyramidal symptoms (EPS) Causes prolactinemia Reduces positive symptoms 3. Phencyclidine (PCP) and Ketamine exert their unique behavioral effects by blocking which of the following receptors? GABA type receptors NRNP 6675 MIDTERM EXAM (YEAR 2022 – 100/100 POINTS) LATEST UPDATE Serotonin receptors NRNP 6675 MIDTERM EXAM (YEAR 2022 – 100/100 POINTS) LATEST UPDATE Dopamine receptors NMDA type receptors 4. The diagnosis used to describe a syndrome characterized by specific signs and symptoms resulting from recent ingestion or exposure
Información del documento
- Subido en
- 8 de febrero de 2024
- Número de páginas
- 57
- Escrito en
- 2023/2024
- Tipo
- Examen
- Contiene
- Preguntas y respuestas